



Contents lists available at ScienceDirect

Bioorganic & Medicinal Chemistry Letters

journal homepage: www.elsevier.com/locate/bmcl

Conformationally constrained opioid ligands: The Dmt-Aba and Dmt-Aia versus Dmt-Tic scaffold

Steven Ballet^a, Debby Feytens^a, Rien De Wachter^a, Magali De Vlaeminck^a, Ewa D. Marczak^b, Severo Salvadori^c, Chris de Graaf^d, Didier Rognan^d, Lucia Negri^e, Roberta Lattanzi^e, Lawrence H. Lazarus^b, Dirk Tourwé^{a,*}, Gianfranco Balboni^f

^a Department of Organic Chemistry, Vrije Universiteit Brussel, Pleinlaan 2, B-1050 Brussels, Belgium

^b Medicinal Chemistry Group, LP, National Institute of Environmental Health Sciences, NC 27709, USA

^c Department of Pharmaceutical Sciences, University of Ferrara, I-44100 Ferrara, Italy

^d Bioinformatics of the Drug, CNRS UMR 7175-LC1, Université Louis Pasteur Strasbourg I, Illkirch F-67401, France

^e Department of Physiology and Pharmacology "Vittorio Ersparmer", Sapienza, University of Rome, 00815 Rome, Italy

^f Department of Pharmaceutical Sciences and Biotechnology Center, University of Cagliari, I-09124 Cagliari, Italy

ARTICLE INFO

Article history:

Received 22 July 2008

Revised 13 November 2008

Accepted 14 November 2008

Available online 19 November 2008

Keywords:

Opioid peptidomimetics
Constrained amino acids

ABSTRACT

Replacement of the constrained phenylalanine analogue 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic) in the opioid Dmt-Tic-Gly-NH-Bn scaffold by the 4-amino-1,2,4,5-tetrahydro-indolo[2,3-c]azepin-3-one (Aia) and 4-amino-1,2,4,5-tetrahydro-2-benzazepin-3-one (Aba) scaffolds has led to the discovery of novel potent μ -selective agonists (Structures **5** and **12**) as well as potent and selective δ -opioid receptor antagonists (Structures **9** and **15**). Both stereochemistry and N-terminal *N,N*-dimethylation proved to be crucial factors for opioid receptor selectivity and functional bioactivity in the investigated small peptidomimetic templates. In addition to the in vitro pharmacological evaluation, automated docking models of Dmt-Tic and Dmt-Aba analogues were constructed in order to rationalize the observed structure–activity data.

© 2008 Elsevier Ltd. All rights reserved.

Conformationally constrained amino acids have found widespread application in search of novel peptidic opioid ligands with minored side-effects.^{1–8} Such residues, inducing enhanced receptor selectivity and affinity, can be subdivided in sterically (e.g., β -methylphenylalanine, β -methyltryptophan, β -methyl-2',6'-dimethyltyrosine) and covalently constrained derivatives [e.g., 2-aminotetralin-2-carboxylic acid (Atc), 2-aminoindane-2-carboxylic acid (Aic), 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic)].⁹ The Dmt-Tic scaffold **1**, in particular, has been recognized as a firmly established template for opioid ligand design.^{3,4} Subtle changes in this scaffold have induced remarkable alterations in opioid receptor selectivity and/or activity, such as enhanced agonism, antagonism, or the acquisition of mixed activities at the opioid subtype receptors (i.e., μ , δ and κ receptors). Replacement of tyrosine by Dmt (2',6'-dimethyl-L-tyrosine) markedly modified

the pharmacological profile of numerous unrelated opioid ligands.^{3,10,11} Next to the crucial impact of Dmt on opioid potency, the introduction of Tic into naturally occurring opioid ligands,^{12–14} led to the conclusion that this conformationally restricted phenylalanine analogue was responsible for the receptor antagonism displayed by Tic-containing structures.

Earlier work in our laboratory involved the replacement of Tic² in Dmt-Tic derivatives **1** by the dipeptidomimetic Aba-Gly (Aba: 4-amino-1,2,4,5-tetrahydro-2-benzazepin-3-one). This substitution, yielding opioid ligands of type **2** (Fig. 1), led to increased receptor selectivities as well as a δ - to μ -receptor affinity shift, relative to the reference Tic derivatives.¹⁵ The main structural difference between the constrained aromatic residues Tic and Aba, consists of the allowed low energy conformations for the amino acid χ_1 space. The Tic residue allows *g*(–) and *g*(+) conformations ($\chi_1 = -60^\circ$ and $+60^\circ$, respectively), whereas Aba limits the side chain orientation to *g*(+) and *trans* ($\chi_1 = 60^\circ$ and 180° , respectively).¹⁶ The same dihedral angles are favoured in the 4-amino-indolo[2,3-c]azepin-3-one (Aia) scaffold which is present in **3**. The heterocyclic core of **3** was recently successfully used for sst_{4/5} selective somatostatin peptidomimetics.¹⁷

In this work, two approaches were followed to change potency, selectivity or functional properties of the previously reported Dmt-

Abbreviations: Aba, 4-amino-1,2,4,5-tetrahydro-2-benzazepin-3-one; Aia, 4-amino-1,2,4,5-tetrahydro-indolo[2,3-c]azepin-3-one; Aic, 2-aminoindane-2-carboxylic acid; Atc, 2-aminotetralin-2-carboxylic acid; Dmt, 2',6'-dimethyl-L-tyrosine; DOR, δ -opioid receptor; EM-1, endomorphin-1; GPI, guinea-pig ileum; MOR, μ -opioid receptor; MVD, mouse vas deferens; Tic, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; TTM, α -helical transmembrane domain 7.

* Corresponding author. Tel.: +32 26293295; fax: +32 26293304.

E-mail address: datourwe@vub.ac.be (D. Tourwé).




Figure 1. Structures of the Dmt-Tic 1, Dmt-Aba 2 and Dmt-Aia 3 scaffolds.

Aba-Gly analogues **2**.¹⁵ In the first approach, the role of charge in the discrimination of opioid receptor selectivity and bioactivity was investigated by the preparation and evaluation of Aba-Asp (negative charge) and Aba-Lys (positive charge) derivatives. In the corresponding Dmt-Tic analogues, the charge of the C-terminal part had substantial effect on δ -selectivity and antagonism.¹⁸ In a second approach, the effects of replacing the benzene ring in the Aba scaffold in **2** by an indole ring, to give **3**, was investigated. This approach was motivated by the fact that, on the one hand, in the bioactive conformation of Tyr¹-Tic²-Phe³- δ -antagonist peptides, the Tic² aromatic ring would correspond to the indole ring in the non-peptide δ -antagonist naltrindole.¹⁹ On the other hand, the Tic² residue in **1** can also correspond to the Phe³ residue in opioid peptides such as dermorphin (Tyr¹-D-Ala²-Phe³-Gly⁴-Tyr⁵-Pro⁶-Ser⁷-NH₂), deltorphin I or II (Tyr¹-D-Ala²-Phe³-Asp⁴-Val⁵-Val⁶-Gly⁷-NH₂ or Tyr¹-D-Ala²-Phe³-Glu⁴-Val⁵-Val⁶-Gly⁷-NH₂, resp.) or endomorphin-2 (EM-2: Tyr¹-Pro²-Phe³-Phe⁴-NH₂). The related analogue endomorphin-1 (EM-1: Tyr¹-Pro²-Trp³-Phe⁴-NH₂) contains a Trp residue at position 3 which may be mimicked by the Aia residue in scaffold **3** (Fig. 1).

The reference structures for this work consisted of peptidomimetics **4** and **5** (Fig. 2).¹⁵ Dmt-Tic-Gly-NH-Bn **4** displays a δ over μ selectivity (Table 1), whereas μ -opioid receptor binding is preferred for the Aba-containing analogue **5**. Substitution of Tic² by Aba in Dmt-Tic ligands reduced δ -opioid receptor affinity, but ligand **5** maintained high μ -opioid receptor affinity and functional bioactivity (Table 1). Peptide mimic **5** (Fig. 2) possesses K_i^μ and IC₅₀(GPI) values comparable to those of the μ -selective endogenous tetrapeptides endomorphin-1 and endomorphin-2.

Three-dimensional structural models of the δ -opioid (DOR) and μ -opioid receptor (MOR) were constructed and refined according to a GPCR modeling procedure previously described,²⁰ using the beta 2 adrenergic receptor crystal structure²¹ as a homology modeling template and using the experimental constraints defined by Mosberg et al.^{22,23} Surflex²⁴ automated docking simulations²⁵ yielded binding modes of the known δ -agonist JOM13 (Tyr¹-c[D-Cys²-Phe³-D-Pen⁴]OH) in DOR (Fig. 3A) and of the known μ -agonist JOM6 (Tyr¹-c(S-Et-S)[D-Cys²-Phe³-D-Pen⁴]NH₂) in MOR (Fig. 4A) which are in line with experimental studies.^{22,23,26–34} In both receptors, the protonated amine group of the ligand forms a complementary H-bond interaction network with D3.32^{28,31} (Ballesteros-Weinstein numbering) and Y7.43,^{30,31} while the Tyr¹ phenol

ring binds in the hydrophobic pocket between Y3.33^{30,33} and W6.48³⁰ and forms an H-bond with H6.52.²⁶ The Phe³ group of JOM6 adopts a trans χ_1 orientation and forms aromatic interactions with W7.35 in MOR,²² while the Phe³ group of JOM13 adopts a gauche (+) orientation and binds in the hydrophobic pocket near H7.36 in DOR.²³ The C-terminal carboxamide group of JOM6 is in close proximity of E5.35 in MOR,²² whereas the C-terminal carboxylate group of JOM13 forms a salt bridge with K5.39 in DOR.²³ Docking poses²⁵ of reference compounds **4** (in DOR, see Fig. 3B) and **5** (in MOR, see Fig. 4B) involved in the same receptor–ligand interactions as JOM13²³ (in DOR, Fig. 3A) and JOM6²² (in MOR, Fig. 4A), respectively, were selected using a receptor–ligand interaction fingerprint (IFP) scoring method³⁵ as described earlier.²⁰ The N-terminal Dmt groups of compounds **4** and **5** form the same H-bond interactions with D3.32 and H6.52 as the N-terminal tyramine groups of JOM6 and JOM13 and bind in the same hydrophobic pocket between Y3.33 and W6.48. The Tic group of DOR-specific compound **4** occupies the same binding pocket near H7.36 as the Phe³ group of JOM13, while the Bn group of compound **4** stacks with W6.58, which plays an important role in DOR-specific agonist binding³⁴ (Fig. 3B). The Aba group of the MOR-specific compound **5**, on the other hand, stacks with W7.35, a residue which plays an important role in MOR-specific agonist binding,³² and occupies the same binding pocket as the Phe³ ring of JOM6²² (Fig. 4). The Bn aromatic ring of compound **5** stacks with the Aba group of the ligand and forms a cation– π interaction with the positively charged nitrogen atom of K5.39²⁷ of MOR (Fig. 4B).

To obtain positively and negatively charged scaffolds, respectively, Aba-Lys **6** and Aba-Asp **7** derivatives were prepared according to previously reported methods.^{15,36} The presence of a positive charge in ligand **6** seemed to be detrimental for binding to the active sites of both μ -opioid and δ -opioid receptors, as witnessed by a 22- to 26-fold decrease in affinity (Table 1, $K_i^\delta = 290.1 \pm 16$ nM and $K_i^\mu = 10.1 \pm 1.3$ nM). Because of the nanomolar range of the μ -affinity, μ -receptor activity was nonetheless verified. The in vitro GPI assay of ligand **6**, measuring the activation of the μ -opioid receptor, reflected this loss in binding by an equivalent observed decrease in potency (IC₅₀ ^{μ} = 3272 $\pm$ 354 nM).

The negative charge in the aspartic acid side chain of the analogous Dmt-Aba-Asp-NH₂ ligand **7**, was even less tolerated by both subtype receptors ($K_i^\delta = 1478 \pm 189$ nM and $K_i^\mu = 629 \pm 210$ nM). Next to a loss in binding, the negative charge also eliminates




Figure 2. Reference compounds Dmt-Tic-NH-Bn **4** and Dmt-Aba-Gly-NH-Bn **5**.¹⁵

Table 1
Receptor affinities, selectivities and functional bioactivity of ligands 4–17

Compounds		Receptor affinity (nM) ^a		Selectivity		Functional bioactivity ^b		
		K_i^δ	K_i^μ	K_i^δ/K_i^μ	K_i^μ/K_i^δ	MVD IC ₅₀ (nM)	MVD (pA ₂)	GPI IC ₅₀ (nM)
4	H-Dmt-Tic-Gly-NH-Bn ^c	0.031 ± 0.002	0.16 ± 0.018		5.2			2.69 ± 0.07
5	H-Dmt-Aba-Gly-NH-Bn ^c	11.0 ± 2.3	0.46 ± 0.07	24		830 ± 70	9.3	51 ± 5
6	H-Dmt-Aba-Lys-NH-Bn	290.1 ± 16 (4)	10.1 ± 1.3 (5)	29		NT		3272 ± 354
7	H-Dmt-Aba-Asp-NH-Bn	1478 ± 189 (3)	629.5 ± 210 (3)	2.3		NT		NT
8	H-Dmt-Aba	367.8 ± 48 (5)	12.4 ± 1.2 (4)	30		NT		631 ± 54
9	N,N(Me) ₂ -Dmt-Aba	20.5 ± 0.67 (4)	64.9 ± 10 (5)		3.2	NA	7.2	NA
10	H-Dmt-Aia-Gly-NH-Bn	357.9 ± 43 (4)	50.0 ± 2.6 (3)	7.2		NT		1795 ± 215
11	H-Dmt-Aia-Gly-O-Bn	4065 ± 410 (3)	243.7 ± 24 (3)	17		NT		NT
12	H-Dmt-D-Aia-Gly-NH-Bn	160.7 ± 23 (4)	3.35 ± 0.28 (3)	48		1500 ± 139 (E _{max} = 80%)		14.9 ± 1.6
13	N,N(Me) ₂ -Dmt-D-Aia-Gly NH-Bn	681 ± 36 (4)	133 ± 18 (5)	5		NT		NT
14	H-Dmt-Aia-Gly-OH	805.9 ± 79 (6)	1450 ± 130 (4)		1.8	NT		NA
15	N,N(Me) ₂ -Dmt-Aia-Gly-OH	6.64 ± 0.89 (5)	874.5 ± 100 (5)		132	NA	8.3	NA
16	H-Dmt-D-Aia-Gly-OH	720 ± 31(4)	2900 ± 187 (5)		4	NT		NT
17	N,N(Me) ₂ -Dmt-D-Aia-Gly-OH	1150 ± 112 (5)	10100 ± 982(6)		8.8	NT		NT

^a The K_i values (nM) were determined according to Cheng and Prusoff,³⁸ using published methods.³⁹ The mean ± SEM values of three to six repetitions are based on independent binding assays conducted in duplicate using five to eight grade doses of peptides with several different synaptosomal preparations.

^b Agonism was expressed as IC₅₀ obtained from dose response curves.⁴⁰ These values represent the mean ± SEM of at least six fresh tissue samples. Deltorphan C and dermorphin were the internal standards for MVD (δ-opioid receptor bioactivity) and GPI (μ-opioid receptor bioactivity) tissue preparations, respectively.

^c Data taken from Ballet et al.¹⁵ NA, not active (>20,000 nM); NT, not tested.




Figure 3. Docking poses of: (A) JOM13 (green carbon atoms) and (B) compound 4 (yellow carbon atoms) in the DOR receptor model. The backbone of transmembrane helices 5, 6, and 7 are represented by magenta ribbons (TM3 is not shown for clarity). Important binding residues are depicted as ball-and-sticks with grey carbon atoms. Oxygen, nitrogen, sulphur and hydrogen atoms are coloured red, blue, orange and cyan, respectively. H-bonds described in the text are depicted by white dots.




Figure 4. Docking poses of: (A) JOM6 (green carbon atoms) and (B) compound 5 (yellow carbon atoms) in the MOR receptor model. Rendering and colour coding are the same as defined for Figure 3.

μ -receptor selectivity (**5** $\rightarrow$ **7**: $K_i^\delta/K_i^\mu = 24 \rightarrow 2.3$. The binding orientation of compound **5** in the μ -receptor presented in Figure 4B suggests that introduction of a positively (compound **6**) or negatively (compound **7**) charged side chain at the Gly position indeed does not enable beneficial interactions with the charged residues at positions 5.35 (Asp in DOR, Glu in MOR), 5.39 (Lys in DOR and MOR), nor 6.58 (Lys in MOR), but instead cause the ligand to clash with TM6 lower in the binding pocket.

The truncation of the Dmt-Aba-Gly-NH-Bn **5**, presenting ligand **8**, results in a moderate binding to and activation of MOR ($K_i^\mu = 12.4 \pm 1.2$ nM, $IC_{50}^\mu = 631 \pm 54$ nM), but affinity for DOR is significantly decreased ($K_i^\delta = 367.8 \pm 48$ nM). According to our docking model, this affinity loss in MOR of compound **8** compared to **5** can be ascribed to the elimination of the favourable cation– π interaction between the C-terminal benzyl group in **5** and the positively charged amine group of K5.39, and the loss of stabilizing intramolecular π – π stacking between the Aba and Bn rings (Fig. 4B). The *N,N*-dimethylation of Dmt-Tic sequences was initially introduced to develop more stable structures, as Tyr-Tic and Dmt-Tic peptides are prone to form diketopiperazines.³ The *N,N*-dimethyl analogue of **8**, ligand **9**, shifts receptor selectivity from the μ - to the δ -opioid receptor and concomitantly converts the activity profile, creating a δ -opioid receptor antagonist, an effect that was also observed in Dmt-Tic analogues.³⁷

The 4-amino-indolo[2,3-*c*]azepin-3-one scaffold (Aia) in **3** can be regarded as a constrained tryptophan residue that limits both χ_1 and χ_2 dihedral angles in the same way as the Aba scaffold does for a phenylalanine residue.^{17,41} Structurally, the introduction of Aia into the opioid pharmacophore can, for example, mimic Trp³ as was shown in the endogenous endomorphin-1 (EM-1: H-Tyr¹-Pro²-Trp³-Phe⁴-NH₂). Although the peptidomimetic [Aia³]EM-1 was determined to be a full agonist in the GPI and MVD assays, a loss in functional bioactivity was observed ($IC_{50}^\mu = 223.8 \pm 3.64$ nM vs. 9.7 ± 2.21 nM for EM-1).⁴¹ To further evaluate the constrained Aia template in opioid ligands, we prepared compounds **10** to **17** according to literature methodologies.^{15,41} The aminobenzazepinone moiety in the most active compound of the series, Dmt-Aba-Gly-NH-Bn **5**, was replaced by the Trp-counterpart Aia and yielded ligand **10** (Table 1). Both δ - and μ -opioid receptor affinities of **10** are situated in the moderate to high nanomolar range, while maintaining MOR selectivity. Only micromolar range potency was displayed when this structure was submitted to the functional GPI assay. The C-terminal ester equivalent of **10**, compound **11**, showed even less affinity for both μ - and δ -opioid receptors, and suggests the amide in **10** to be involved in hydrogen bonding and/or favorable directing of the terminal benzyl group. The substitution of the benzene ring of the Aba residue in **5** by the indole ring in **10** positions the benzene ring of the Aia residue further away from the MOR specific binding pocket between W7.35 and H7.36 (Fig. 4B), but also results in a slightly different orientation of the *N*-benzyl substituent, which may weaken the cation– π interaction with the K5.39 residue of MOR. This is shown in the superpositions of the binding conformation of **5** and **10** in Figure 5. The combination of both effects may explain the loss in binding affinity observed for **10** versus **5**.

The importance of the Aia α -stereochemistry was investigated by switching to the *D*-isomer of Aia. *D*-Aia analogue **12** not only yielded a highly selective derivative, its μ -bioactivity is comparable to that of the potent endogenous peptide EM-1 (IC_{50}^μ **12** = 14.9 ± 1.6 nM and IC_{50}^μ EM-1 = 9.7 ± 2.21 nM⁴¹). This observation suggests that the *D*-configuration of the Aia residue might be able to restore a binding pose as observed for **5**. *N,N*-dimethylation of **12**, resulting in ligand **13**, significantly decreased μ -receptor binding and was detrimental for receptor selectivity, an observation which was also made *N,N*(Me)₂-Dmt-Tic-amides.³⁷ Apparently the extensive hydrogen bonding network that is observed between




Figure 5. Superposition of the docking poses of compound **5** (blue) and compound **10** (red) in the MOR receptor model.²⁵

the primary amine of Dmt in **5** (Fig. 4 B) is disturbed by the *N,N*-dimethylation.

The presence of a C-terminal carboxylic acid in opioid ligands is known to induce δ -receptor selectivity due to an unfavorable interaction between the ligands' carboxylate and residue E5.35 in the μ -opioid receptor.⁴² This electrostatic interaction is most probably responsible for the δ -opioid receptor preference of ligands **14–17**. Only one of these ligands, compound **15**, efficiently binds to DOR ($K_i^\delta = 6.64 \pm 0.89$ nM). It showed potent antagonist properties ($pA_2 = 8.3$), confirming that *N,N*-dimethylation of Dmt is able to convert a δ -agonist into an antagonist.³⁷ The comparison of ligands **15** and **17** clearly shows the crucial importance of stereochemistry in receptor binding efficiency.

In conclusion, of our two approaches to change the pharmacological profile of Dmt-Aba-Gly analogues, the one involving the introduction of both positive (Aba-Lys ligand **6**) and negative (Aba-Asp ligand **7**) charge proved to be detrimental for binding to and activation of the μ - and δ -opioid receptors, relative to the reference compound **5**. This is in sharp contrast to previous observations in the Dmt-Tic series of analogues, where a positive charge in the side chain of the C-terminal amino acid considerably increased the μ -affinity while maintaining δ -affinity. A negative charge in these Dmt-Tic analogues was shown to be important for δ -affinity, but prevented these ligands from interacting with the μ -receptor.¹⁸ These findings could be rationalized by the different binding modes that were observed for the receptor-docked structures between the Tic-containing versus the Aba-containing analogues. The C-terminal benzyl group in **5**, on the other hand, was shown to be important for bioactivity at the MOR as demonstrated by the reduced potency of truncated ligand **8**, a feature that was also rationalized by the binding mode of these ligands to the MOR.

In contrast, our second approach to investigate the importance of replacing the benzene ring in the Aba scaffold by an indole ring, which is equivalent to replacing a constrained Phe residue by a constrained Trp residue, resulted in some interesting new opioid ligands. The replacement of Aba in **5** by Aia in **10** resulted in a drop of affinity for both receptors however, the change of chirality to *D*-Aia in **12** resulted in a μ -opioid receptor selective agonist with a potency comparable to the endogenous opioid endomorphin-1. The indole ring of Aia is therefore is more likely to mimic the Trp³ residue in the μ -agonist endomorphin-1 than the indole in the δ -antagonist naltrindole. Finally, two novel *N,N*-dimethylated scaffolds **9** and **15** proved to be δ -selective antagonists, which confirms that *N,N*-dimethylation of Dmt is able to induce antagonist properties.¹⁸

Acknowledgments

D. Feytens is a Research Assistant for the Fund for Scientific Research – Flanders (Belgium). This work was supported in part by the Intramural Research Program of NIH and NIEHS and by the Fund for Scientific Research – Flanders (Belgium, Grants G.0036.04 and G.0008.08) and European grant 'Normolife' (LSHC-CT-2006-037733).

References and notes

1. Hruby, V. J.; Li, G. G.; Haskell-Luevano, C.; Shenderovich, M. *Biopolymers* **1997**, *43*, 219.
2. Birkas, E.; Kertesz, I.; Toth, G.; Bakota, L.; Gulya, K.; Szucs, M. *Neuropeptides* **2008**, *42*, 57.
3. Bryant, S. D.; Jinsmaa, Y.; Salvadori, S.; Okada, Y.; Lazarus, L. H. *Biopolymers* **2003**, *71*, 86.
4. Schiller, P. W.; Weltrowska, G.; Berezowska, I.; Nguyen, T. M. D.; Wilkes, B. C.; Lemieux, C.; Chung, N. N. *Biopolymers* **1999**, *51*, 411.
5. Schiller, P. W.; Fundytus, M. E.; Merovitz, L.; Weltrowska, G.; Nguyen, T. M. D.; Lemieux, C.; Chung, N. N.; Coderre, T. J. *J. Med. Chem.* **1999**, *42*, 3520.
6. Schiller, P. W.; Nguyen, T. M. D.; Berezowska, I.; Dupuis, S.; Weltrowska, G.; Chung, N. N.; Lemieux, C. *Eur. J. Med. Chem.* **2000**, *35*, 895.
7. Schiller, P. W. *AAPS J.* **2005**, *7*, E560.
8. Tóth, G.; Iloja, E.; Tömböly, C.; Ballet, S.; Tourwé, D.; Péter, A.; Martinek, T.; Chung, N. N.; Schiller, P. W.; Benyhe, S.; Borsodi, A. *J. Med. Chem.* **2007**, *50*, 328.
9. Gibson, S. E.; Guillo, N.; Tozer, M. J. *Tetrahedron* **1999**, *55*, 585.
10. Guerrini, R.; Capasso, A.; Sorrentino, L.; Anacardio, R.; Bryant, S. D.; Lazarus, L. H.; Attila, M.; Salvadori, S. *Eur. J. Pharmacol.* **1996**, *302*, 37.
11. Okada, Y.; Tsuda, Y.; Fujita, Y.; Yokoi, T.; Sasaki, Y.; Ambo, A.; Konishi, R.; Nagata, M.; Salvadori, S.; Jinsmaa, Y.; Bryant, S. D.; Lazarus, L. H. *J. Med. Chem.* **2003**, *46*, 3201.
12. Tancredi, T.; Salvadori, S.; Amodeo, P.; Picone, D.; Lazarus, L. H.; Bryant, S. D.; Guerrini, R.; Marzola, G.; Temussi, P. A. *Eur. J. Biochem.* **1994**, *224*, 241.
13. Lu, Y. X.; Nguyen, T. M. D.; Weltrowska, G.; Berezowska, I.; Lemieux, C.; Chung, N. N.; Schiller, P. W. *J. Med. Chem.* **2001**, *44*, 3048.
14. Guerrini, R.; Capasso, A.; Marastoni, M.; Bryant, S. D.; Cooper, P. S.; Lazarus, L. H.; Temussi, P. A.; Salvadori, S. *Bioorg. Med. Chem.* **1998**, *6*, 57.
15. Ballet, S.; Salvadori, S.; Trapella, C.; Bryant, S. D.; Jinsmaa, Y.; Lazarus, L. H.; Negri, L.; Giannini, E.; Lattanzi, R.; Tourwé, D.; Balboni, G. *J. Med. Chem.* **2006**, *49*, 3990.
16. Tourwé, D.; Verschuere, K.; Frycia, A.; Davis, P.; Porreca, F.; Hruby, V. J.; Tóth, G.; Jaspers, H.; Verheyden, P.; Van Binst, G. *Biopolymers* **1996**, *38*, 1.
17. Feytens, D.; Cescato, R.; Reubi, J. C.; Tourwé, D. *J. Med. Chem.* **2007**, *50*, 3397.
18. Balboni, G.; Salvadori, S.; Guerrini, R.; Negri, L.; Giannini, E.; Bryant, S. D.; Jinsmaa, Y.; Lazarus, L. H. *J. Med. Chem.* **2004**, *47*, 4066.
19. Wilkes, B. C.; Schiller, P. W. *Biopolymers* **1995**, *37*, 391.
20. de Graaf, C.; Foata, N.; Engkvist, O.; Rognan, D. *Proteins* **2008**, *71*, 599.
21. Cherezov, V.; Rosenbaum, D. M.; Hanson, M. A.; Rasmussen, S. G. F.; Thian, F. S.; Kobilka, T. S.; Choi, H. J.; Kuhn, P.; Weis, W. I.; Kobilka, B. K.; Stevens, R. C. *Science* **2007**, *318*, 1258.
22. Fowler, C. B.; Pogozheva, I. D.; Lomize, A. L.; LeVine, H.; Mosberg, H. I. *Biochemistry* **2004**, *43*, 15796.
23. Mosberg, H. I. *Biopolymers* **1999**, *51*, 426.
24. Jain, A. N. *J. Comput. Aided Mol. Des.* **2007**, *21*, 281.
25. Ligands were automatically docked into the DOR and MOR receptor models using standard parameters of Surflex v2.11. Twenty poses were generated for each ligand. The binding site (protomol file) was defined by providing a list of cavity residues in 5 Å distance from JOM6 (in MOR) or JOM13 (in DOR) in the refined receptor–ligand structure.
26. Spivak, C. E.; Beglan, C. L.; Seidleck, B. K.; Hirshbein, L. D.; Blaschak, C. J.; Uhl, G. R.; Surratt, C. K. *Mol. Pharmacol.* **1997**, *52*, 983.
27. Chen, C. G.; Yin, Y. L.; deRiel, J. K.; Desjarlais, R. L.; Raveglia, L. F.; Zhu, J. M.; LiuChen, L. Y. *J. Biol. Chem.* **1996**, *271*, 21422.
28. Li, J. G.; Chen, C. G.; Yin, J. L.; Rice, K.; Zhang, Y.; Matecka, D.; de Riel, J. K.; Desjarlais, R. L.; Liu-Chen, L. Y. *Life Sci.* **1999**, *65*, 175.
29. Surratt, C. K.; Johnson, P. S.; Moriwaki, A.; Seidleck, B. K.; Blaschak, C. J. *J. Biol. Chem.* **1994**, *269*, 20548.
30. Befort, K.; Tabbara, L.; Kling, D.; Maigret, B.; Kieffer, B. L. *J. Biol. Chem.* **1996**, *271*, 10161.
31. Befort, K.; Zilliox, C.; Filliol, D.; Yue, S. Y.; Kieffer, B. L. *J. Biol. Chem.* **1999**, *274*, 18574.
32. Bonner, G.; Meng, F.; Akil, H. *Eur. J. Pharmacol.* **2000**, *403*, 37.
33. Xu, H.; Lu, Y. F.; Partilla, J. S.; Zheng, Q. X.; Wang, J. B.; Brine, G. A.; Carroll, F. I.; Rice, K. C.; Chen, K. X.; Chi, Z. Q.; Rothman, R. B. *Synapse* **1999**, *32*, 23.
34. Valiquette, M.; Vu, H. K.; Yue, S. Y.; Wahlestedt, C.; Walker, P. J. *J. Biol. Chem.* **1996**, *271*, 18789.
35. Marcou, G.; Rognan, D. *J. Chem. Inf. Model.* **2007**, *47*, 195.
36. Van Rompaey, K.; Van den Eynde, I.; De Kimpe, N.; Tourwé, D. *Tetrahedron* **2003**, *59*, 4421.
37. Salvadori, S.; Guerrini, R.; Balboni, G.; Bianchi, C.; Bryant, S. D.; Cooper, P. S.; Lazarus, L. H. *J. Med. Chem.* **1999**, *42*, 5010.
38. Cheng, Y.; Prusoff, W. H. *Biochem. Pharmacol.* **1973**, *22*, 3099.
39. Salvadori, S.; Balboni, G.; Guerrini, R.; Tomatis, R.; Bianchi, C.; Bryant, S. D.; Cooper, P. S.; Lazarus, L. H. *J. Med. Chem.* **1997**, *40*, 3100.
40. Kosterlitz, H. W.; Watt, A. J. *Br. J. Pharmacol.* **1968**, *33*, 266.
41. Pulka, K.; Feytens, D.; Van den Eynde, I.; De Wachter, R.; Kosson, P.; Misicka, A.; Lipkowski, A.; Chung, N. N.; Schiller, P. W.; Tourwé, D. *Tetrahedron* **2007**, *63*, 1459.
42. Mosberg, H. I.; Fowler, C. B. *J. Pept. Res.* **2002**, *60*, 329.